EDITORIAL
Latent Tuberculosis in the light of the New International Guidelines
 
More details
Hide details
1
Assistant Professor in Pulmonary Medicine, Respiratory Infections Unit, Pulmonary Medicine Clinic, Aristotle University of Thessaloniki
CORRESPONDING AUTHOR
Katerina Manika   

Respiratory Infections Unit Pulmonary Medicine Clinic Aristotle University of Thessaloniki G. Papanicolaou Hospital, 57010 Exohi, Thessaloniki, Greece
 
Pneumon 2015;28(3):218–220
 
 
REFERENCES (15)
1.
World health Organisation. Guidelines on the management of latent tuberculosis infection. WHO/HTM/TB/2015.01.
 
2.
Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med 2015;372:2127-35.
 
3.
Achkar JM, Jenny-Avital ER. Incipient and Subclinical Tuberculosis: Defining Early Disease States in the Context of Host Immune Response. J Infect Dis 2011;204:S1179–86.
 
4.
Shea KM, Kammerer JS, Winston CA, Navin TR, Horsburgh CR Jr. Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. Am J Epidemiol 2014;179:216-25.
 
5.
Marais BJ, Schaaf S, Menzies D. Prevention of TB in areas with high inceidence. Eur Respir Monogr 2012;58:84-94.
 
6.
Pai M, Kunimoto D, Jamieson F, Menzies D. Chapter 4: Diagnosis of latent tuberculosis infection. In: Canadian Tuberculosis Standards, 7th edition., Can Respir J 2013;20:s23A-34A.
 
7.
U.S. Department of Health and Human Services. Centers for Disease Control and Prevention National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Latent Tuberculosis Infection: A Guide for Primary Health Care Providers. 2013.
 
8.
ATS/CDC. Targeted tuberculin testing and treatment of latent TB infection. Am J Respir Crit Care Med 2000;161:S221-47.
 
9.
Erkens CG, Kamphorst M, Abubakar I, et al. Tuberculosis contact investigation in low prevalence countries: a European consensus. Eur Respir J 2010;36:925-49.
 
10.
Bothamley GH, Ditiu L, Migliori GB, Lange C, TBNET contributors. Active case finding of tuberculosis in Europe: a Tuberculosis Network European Trials Group (TBNET) survey Eur Respir J 2008;32:1023–30.
 
11.
Diel R, Loddenkemper R, Meywald-Walter K, Gottschalk R, Nienhaus A. Comparative Performance of Tuberculin Skin Test, QuantiFERON-TB-Gold In Tube Assay, and T-Spot.TB Test in Contact Investigations for Tuberculosis. CHEST 2009;135:1010–18.
 
12.
Comstock GW. How much isoniazid is needed for prevention of tuberculosis among imunocompetent adults? Int J Tuberc Lung Dis 1999;10:847-50.
 
13.
Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV persons. Cochrane Daabase Syst Rev 2000;(2):CD001363.
 
14.
Stagg HR, Zenner D, Harris RJ, Munoz L, Lipman MC, Abubakar I. Treatment of Latent Tuberculosis Infection. A Network Metaanalysis. Ann Intern Med 2014;161:419-28.
 
15.
Menzies D, Alvarez GG, Khan Kamran. Chapter 6: Treatment of latent tuberculosis infection. In: Canadian Tuberculosis Standards, 7th edition. Can Respir J 2013;20:s44A-53A.
 
eISSN:1791-4914
ISSN:1105-848X